|Bid||0.11 x 800|
|Ask||21.05 x 1000|
|Day's Range||17.60 - 18.50|
|52 Week Range||17.60 - 32.34|
|Beta (5Y Monthly)||1.49|
|PE Ratio (TTM)||435.95|
|Earnings Date||Feb 09, 2022 - Feb 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 09, 2015|
|1y Target Est||33.44|
Subscribe to Yahoo Finance Plus to view Fair Value for CRYLearn more
CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that members of management will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 18, 2021. Due to the format of this event no webcast will be available.
The mean of analysts' price targets for CryoLife (CRY) points to a 50.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
This is Pat Mackin CEO of CryoLife. The On-X product line growth was led by the On-X aortic valve revenue growth in North America, which grew 16% compared to 2019. Second, our cardiac tissue declined 10% in the third quarter compared to 2019, resulting from a backlog in review of donor and tissue charge to release this tissue, which, as you will recall, had been temporarily quarantine as a result of our previously discussed Tris issue.